Denne siden er tilgjengelig på flere språk
Select Language

Duallisting of Bone Therepeutics in Brussels and Paris


As of 6 February 2015, the Biotech company Bone Therapeutics is listed both on Brussels and Paris. To celebrate this event, CEO Enrico Bastianelli opened the markets with a Bell Ceremony. Wim Goemaere, CFO, had the honor to write the first opening price on the blackboard. Minister Jean-Claude Marcourt, Vice-Minister-President and Minister of Economy of the Walloon Government was our guest of honour.

Bone Therapeutics raised €32.2M in a 2,5 oversubscribed successful IPO on Euronext Brussels and Paris. The reference price was fixed at €16. Market cap amounts to €104.8M on the day of its introduction. With the funds, Bone Therapeutics will accelerate development of their innovative bone cell therapy products for fracture repair and prevention.

Bone Therapeutics  is a biotechnology company and specializes in the development of cell therapy products  for the treatment of osteo-articular diseases and regeneration of bone tissue, based on a technological platform permitting the production of osteoblastic cells from adult stem cells. This therapeutic domain concerns bone reconstruction application and the treatment of diseases such as osteoporosis.

The ticker code is : BOTHE.

If you would like to find out more :

EnterNext is the most active European market place in the Life Sciences sector with a market share close to 30% in terms of capital raised at IPO.   The biotech franchise listed on Enternext represents over €6.2bn in market capitalisation for 31 issuers.  At Enternext Brussels,  7 Biotech companies represent €2.2bn in market capitalisation. In the recent years, our Next Biotech Index has outperformed most of the main European indices.